Wang HB - Search Results

1

[Inhibitory effect of ginsenoside Rg3 on the tube-like structure formation in human nasopharyngeal carcinoma HNE-1 cell line in vitro].

Wang HB, Lin YC, Zeng D, Lin W, Hong CQ, Lin WZ, Chen JY. Wang HB, et al. Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):739-42. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21163062 Chinese.

2

[The efficacy of vinorelbine plus cisplatin in the treatment of 48 cases of advanced non-small cell lung cancer].

Lin Y, Lin Y, Lin W, Wang H, Zeng D, Lin S, Huo X. Lin Y, et al. Zhongguo Fei Ai Za Zhi. 2005 Feb 20;8(1):51-3. doi: 10.3779/j.issn.1009-3419.2005.01.12. Zhongguo Fei Ai Za Zhi. 2005. PMID: 21187026 Free article. Chinese.

3

[Inhibitory effects of zoledronic acid on cell proliferation and invasion in human nasopharyngeal carcinoma cell line HNE1].

Li XY, Lin YC, Huang WL, Wang HB, Lin W, Hong CQ, Chen JY. Li XY, et al. Among authors: wang hb. Zhonghua Yi Xue Za Zhi. 2011 Aug 30;91(32):2278-82. Zhonghua Yi Xue Za Zhi. 2011. PMID: 22094096 Chinese.

4

Zoledronic acid inhibits human nasopharyngeal carcinoma cell proliferation by activating mitochondrial apoptotic pathway.

Li XY, Lin YC, Huang WL, Lin W, Wang HB, Lin WZ, Lin SL. Li XY, et al. Among authors: wang hb. Med Oncol. 2012 Dec;29(5):3374-80. doi: 10.1007/s12032-012-0281-1. Epub 2012 Jun 23. Med Oncol. 2012. PMID: 22729369

5

[Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon human nasopharyngeal carcinoma cell line HNE1].

Huang WL, Li XY, Wang HB, Lin W, Lin WZ, Lin SL, Lin YC. Huang WL, et al. Among authors: wang hb. Zhonghua Yi Xue Za Zhi. 2012 Apr 24;92(16):1133-7. Zhonghua Yi Xue Za Zhi. 2012. PMID: 22781776 Chinese.

6

Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.

Li X, Lin W, Wang H, Lin W, Lin S, Lin Y. Li X, et al. Med Oncol. 2013 Dec;30(4):746. doi: 10.1007/s12032-013-0746-x. Epub 2013 Oct 13. Med Oncol. 2013. PMID: 24122256 Clinical Trial.

7

Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.

Li X, Wang H, Lin W, Xu Q. Li X, et al. Curr Med Res Opin. 2014 Nov;30(11):2295-304. doi: 10.1185/03007995.2014.909392. Epub 2014 Apr 30. Curr Med Res Opin. 2014. PMID: 24701984 Review.

8

Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.

Lin WZ, Xu QN, Wang HB, Li XY. Lin WZ, et al. Among authors: wang hb. Breast Cancer. 2017 May;24(3):345-352. doi: 10.1007/s12282-017-0770-3. Epub 2017 Mar 21. Breast Cancer. 2017. PMID: 28324247 Review.

9

Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion.

Li Z, Lin Y, Chi X, Xu M, Wang H. Li Z, et al. Lung Cancer. 2021 Mar;153:174-175. doi: 10.1016/j.lungcan.2021.01.001. Epub 2021 Jan 8. Lung Cancer. 2021. PMID: 33472762 No abstract available.

10

Identification of a novel LRRC4C-ALK fusion in lung adenocarcinoma and outcome of the response to anaplastic lymphoma kinase inhibitors.

Wang H, Li Z, Qi X, Wang W, Lin Y. Wang H, et al. J Gene Med. 2021 Mar;23(3):e3316. doi: 10.1002/jgm.3316. Epub 2021 Feb 8. J Gene Med. 2021. PMID: 33559138 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,442 results

Search Page

Filters